It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Most cerebellar ataxias (CAs) are incurable neurological disorders, resulting in a lack of voluntary control by inflamed or damaged cerebellum. Although CA can be either directly or indirectly related to cerebellar inflammation, there is no suitable animal model of CA with neuroinflammation. In this study, we evaluated the utility of an intracerebellar injection of lipopolysaccharide (LPS) to generate an animal model of inflammatory CA. We observed that LPS administration induced the expression of pro-inflammatory molecules following activation of glial cells. In addition, the administration of LPS resulted in apoptotic Purkinje cell death and induced abnormal locomotor activities, such as impaired motor coordination and abnormal hindlimb clasping posture. Our results suggest that intracerebellar LPS administration in experimental animals may be useful for studying the inflammatory component of CA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kyungpook National University, Brain Science and Engineering Institute, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
2 Kyungpook National University, School of Life Sciences, BK21 Plus KNU Creative BioResearch Group, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
3 Kyungpook National University, Department of Pharmacology, Brain Science and Engineering Institute, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
4 Kyungpook National University, Brain Science and Engineering Institute, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556); Kyungpook National University, Department of Pharmacology, Brain Science and Engineering Institute, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
5 Corestem Inc., Bioengineering Institute, Seoul, Republic of Korea (GRID:grid.497755.d)
6 Kyungpook National University, Brain Science and Engineering Institute, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556); Kyungpook National University, Department of Neurology, School of Medicine, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)
7 Kyungpook National University, Brain Science and Engineering Institute, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556); Kyungpook National University, School of Life Sciences, BK21 Plus KNU Creative BioResearch Group, Daegu, Republic of Korea (GRID:grid.258803.4) (ISNI:0000 0001 0661 1556)